Chemotherapy-related thinking and memory changes during treatment for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, single-center project enrolling adult patients with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma who are receiving fixed-duration first-line chemotherapy and their matched relatives as controls. The protocol is designed to document cognitive symptoms such as memory problems, slowed thinking, attention and language difficulties using standardized tests and questionnaires at baseline and follow-up timepoints during treatment. Key exclusions include known or suspected cognitive disorders prior to chemotherapy and severe neurological or psychiatric disease. The comparison with a closely matched relative control aims to help isolate chemotherapy-related effects on cognition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient group inclusion criteria:

  * adult patient with acute myeloid leukemia, Hodgkin's lymphoma, or non-Hodgkin's lymphoma;
  * patient receiving a fixed-duration first-line chemotherapy;
  * patient affiliated or beneficiary of a social security scheme; .signed inform consent form.
* Control group inclusion criteria:

  * adult;
  * patient's relative (spouse, brother, sister, friend, etc.);
  * less than 5 years of difference with the patient;
  * same educational level (\< baccalaureate/high school degree, baccalaureate/high school degree level, 2-year university degree, \> 2-year university degree);
  * person affiliated or beneficiary of a social security scheme;
  * signed informed consent form

Exclusion Criteria:

* Patient group exclusion criteria:

  * no patient's relative for the control group;
  * known or suspective cognitive disorders prior to chemotherapy;
  * history of severe neurological or psychiatric disorders (e.g., severe depression); .previous chemotherapy;
  * previous brain radiotherapy;
  * ongoing treatments affecting cognition;
  * patient unable to read;
  * patient not speaking French;
  * person deprived of liberty by judicial or administrative decision;
  * person under forced psychiatric care;
  * person under legal protection measures;
  * person unable to express consent; .pregnant or breastfeeding woman.
* Control group exclusion criteria:

  * known or suspected cognitive disorders;
  * history of severe neurological or psychiatric disorder (e.g., severe depression); .previous chemotherapy;
  * previous brain radiotherapy;
  * ongoing treatments affecting cognition;
  * person unable to read;
  * person not speaking French;
  * person deprived of liberty by judicial or administrative decision;
  * person under forced psychiatric care;
  * person under legal protection measures;
  * person unable to express consent;
  * pregnant or breastfeeding woman."

Where it's running

• University Hospital of Angers
  Angers, Maine et Loire, France Recruiting

Study contacts

• Study coordinator: SCHMIDT ALINE, MD, PhD
• Email: AlSchmidt@chu-angers.fr
• Phone: 2 41 35 44 82

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stopping immunoglobulin replacement with or without antibiotics to prevent infections in blood cancer patients

  This trial tests if stopping immunoglobulin replacement, with or without daily preventive antibiotics, is safe and keeps infections low in people with myeloma, leukemia, or non-Hodgkin's lymphoma who have been on Ig therapy.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202091

• Preventing infections in people with blood cancers using antibiotics or immunoglobulin

  This project tests whether giving regular intravenous immunoglobulin or prophylactic antibiotics better prevents infections in people with myeloma, non-Hodgkin lymphoma, or leukemia who have not yet started immunoglobulin replacement.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202078

• Antibiotics versus immunoglobulin to prevent infections in people with blood cancers

  This trial tests whether taking preventive antibiotics instead of regular IV immunoglobulin can prevent infections in people with myeloma, non-Hodgkin lymphoma, or leukemia.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202065

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.